Search research articles
Contact Us
Filters
Showing results (51-60 of 74) with videos related to
Page
of 8
Sort By:
The Journal of Clinical Psychiatry
|
May 16, 2020
Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I)
Dong-Jing Fu, Dawn F Ionescu, Xiang Li, et al.
The International Journal of Neuropsychopharmacology
|
August 30, 2020
Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II)
Dawn F Ionescu, Dong-Jing Fu, Xin Qiu, et al.
The Journal of Clinical Psychiatry
|
August 31, 2016
Impact of Paliperidone Palmitate Versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans with Schizophrenia
Yinong Young-Xu, Mei Sheng Duh, Erik Muser, et al.
Schizophrenia Research
|
November 29, 2020
Consistency checks to improve measurement with the Personal and Social Performance Scale (PSP)
Jonathan Rabinowitz, Mark Opler, Alon A Rabinowitz, et al.
Pharmacogenetics and Genomics
|
February 26, 2015
Large-scale candidate gene study to identify genetic risk factors predictive of paliperidone treatment response in patients with schizophrenia
Dai Wang, Dong-Jing Fu, Xiaodong Wu, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
May 12, 2023
Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study
Naim Zaki, Li Nancy Chen, Rosanne Lane, et al.
Pharmacogenomics
|
February 28, 2007
Comprehensive assessment of metabolic enzyme and transporter genes using the Affymetrix Targeted Genotyping System
Carmen Dumaual, Xin Miao, Thomas M Daly, et al.
CNS Drugs
|
August 9, 2023
Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study
Meredith Castro, Samuel T Wilkinson, Rayan K Al Jurdi, et al.
Asia-Pacific Psychiatry : Official Journal of the Pacific Rim College of Psychiatrists
|
September 29, 2023
Efficacy and safety of esketamine nasal spray in addition to standard of care in patients with major depressive disorder who have active suicidal ideation with intent: A subgroup analysis of the Asian cohort of ASPIRE I (a randomized, double-blind, placebo-controlled study)
Jin Pyo Hong, Akramul Zikri Abd Malek, Cheng-Ta Li, et al.
Journal of Affective Disorders
|
February 1, 2022
Consistency checks to improve measurement with the Hamilton Rating Scale for Depression (HAM-D)
Jonathan Rabinowitz, Janet B W Williams, Ariana Anderson, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 74) with videos related to
Sort By:
Page
of 8
The Journal of Clinical Psychiatry
|
May 16, 2020
Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I)
Dong-Jing Fu, Dawn F Ionescu, Xiang Li, et al.
The International Journal of Neuropsychopharmacology
|
August 30, 2020
Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II)
Dawn F Ionescu, Dong-Jing Fu, Xin Qiu, et al.
The Journal of Clinical Psychiatry
|
August 31, 2016
Impact of Paliperidone Palmitate Versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans with Schizophrenia
Yinong Young-Xu, Mei Sheng Duh, Erik Muser, et al.
Schizophrenia Research
|
November 29, 2020
Consistency checks to improve measurement with the Personal and Social Performance Scale (PSP)
Jonathan Rabinowitz, Mark Opler, Alon A Rabinowitz, et al.
Pharmacogenetics and Genomics
|
February 26, 2015
Large-scale candidate gene study to identify genetic risk factors predictive of paliperidone treatment response in patients with schizophrenia
Dai Wang, Dong-Jing Fu, Xiaodong Wu, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
May 12, 2023
Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study
Naim Zaki, Li Nancy Chen, Rosanne Lane, et al.
Pharmacogenomics
|
February 28, 2007
Comprehensive assessment of metabolic enzyme and transporter genes using the Affymetrix Targeted Genotyping System
Carmen Dumaual, Xin Miao, Thomas M Daly, et al.
CNS Drugs
|
August 9, 2023
Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study
Meredith Castro, Samuel T Wilkinson, Rayan K Al Jurdi, et al.
Asia-Pacific Psychiatry : Official Journal of the Pacific Rim College of Psychiatrists
|
September 29, 2023
Efficacy and safety of esketamine nasal spray in addition to standard of care in patients with major depressive disorder who have active suicidal ideation with intent: A subgroup analysis of the Asian cohort of ASPIRE I (a randomized, double-blind, placebo-controlled study)
Jin Pyo Hong, Akramul Zikri Abd Malek, Cheng-Ta Li, et al.
Journal of Affective Disorders
|
February 1, 2022
Consistency checks to improve measurement with the Hamilton Rating Scale for Depression (HAM-D)
Jonathan Rabinowitz, Janet B W Williams, Ariana Anderson, et al.
Page
of 8